Edit:

Edit Target: 209

pid
Abbr	MO
Name	Moringa oleifera
Type
Features

Product : MO, Moringa oleifera

The leaves, seeds, and pods of the Moringa oleifera plant contain a variety of bioactive compounds, including flavonoids, phenolic acids, and saponins, which have been shown to have anti-inflammatory, antioxidant, and anti-proliferative effects.
Moringa oleifera extracts on various types of cancer: Breast, Lung, Colon, Prostate

Moringa (Moringa oleifera) is not a single compound.
Cancer-related data are primarily from:
-Leaf extracts (polyphenols, quercetin, kaempferol)
-Isothiocyanates (e.g., moringin)
-Glucosinolates
-Alkaloids and other secondary metabolites
Mechanistically it behaves as a mixed redox-modulating phytochemical extract, not a strong direct cytotoxin.

Moringa oleifera — a nutrient-rich medicinal and food plant of the Moringaceae family whose leaves, seeds, pods, and other tissues contain complex mixtures of glucosinolates, isothiocyanates, flavonoids, phenolic acids, alkaloids, sterols, and other phytochemicals. It is a botanical/nutraceutical rather than a single molecular agent; common abbreviations include MO and MOL for Moringa oleifera and Moringa oleifera leaf. The leaves are the most commonly consumed and studied oral preparation. Important bioactives include glucomoringin and its myrosinase-derived isothiocyanate moringin, together with quercetin- and kaempferol-related flavonoids. Anticancer activity is predominantly preclinical and varies substantially with plant part, extraction method, phytochemical composition, and concentration.

Primary mechanisms (ranked):

Induction of mitochondrial and caspase-dependent apoptosis, including Bax ↑, Bcl-2 ↓, mitochondrial membrane potential ↓, cytochrome-c release, and caspase activation.
Redox modulation, including ROS ↑ in several cancer models but antioxidant/ROS-lowering effects in many normal-cell and tissue models; direction is strongly preparation- and context-dependent.
Suppression of pro-survival inflammatory signaling, particularly NF-κB and associated inflammatory mediators.
Cell-cycle arrest through p21, p53, cyclin/CDK, and related regulatory mechanisms, commonly involving G1 or G2/M arrest depending on model.
Modulation of PI3K/AKT, MEK/ERK, JNK/p38 MAPK, and other growth/stress signaling pathways.
Suppression of invasion, migration, angiogenesis, and metastasis-associated signaling in selected preclinical models.
Chemosensitization, including enhanced cisplatin cytotoxicity in pancreatic cancer cells; evidence remains preclinical.
NRF2/ARE activation and induction of antioxidant/detoxification enzymes, primarily relevant to cytoprotection and chemoprevention; its effect in established tumors is context-dependent rather than uniformly anticancer.

Bioavailability / PK relevance: Oral exposure cannot be represented by a single PK profile because Moringa is a heterogeneous botanical preparation. Glucomoringin requires hydrolysis, including by myrosinase, to generate moringin and related isothiocyanate activity. Processing and extraction conditions substantially alter isothiocyanate delivery. Human pharmacokinetic data for the major putative anticancer constituents remain limited, and standardized preparations are required for meaningful dose comparisons.

In-vitro vs systemic exposure relevance: Many cancer-cell experiments use concentrated crude extracts in the tens to hundreds of µg/mL range and sometimes approximately 0.75 mg/mL or higher. Equivalent circulating concentrations of whole Moringa extract after ordinary oral leaf consumption have not been demonstrated and are unlikely to be directly reproduced systemically. Purified isothiocyanates and locally generated gastrointestinal metabolites should therefore be distinguished from crude-extract concentration experiments when evaluating clinical plausibility.

Clinical evidence status: Cancer — preclinical. Antiproliferative and antitumor effects have been demonstrated in numerous cell models and a smaller number of animal studies, but controlled clinical evidence establishing Moringa as a cancer treatment or cancer adjunct is lacking. Human studies exist mainly in metabolic, nutritional, inflammatory, and maternal-health settings rather than oncology. Moringa is consumed as food and marketed as a botanical supplement, not as an approved anticancer drug. Leaf preparations have generally been well tolerated in short human studies, but long-term high-dose safety, standardized oncology dosing, drug interactions, and the safety of non-leaf preparations are insufficiently characterized.

Moringa oleifera – Bioactive Ingredients and Concentrations

Rank	Active Ingredient	Class	Concentration mg/g DW	Amount per 5 g	Principal Activity	Notes
1	Glucomoringin	Glucosinolate	33.9–59.4	169.5–297 mg	Precursor of moringin; potential anti-inflammatory and anticancer activity	Selected reported leaf measurements. Highly dependent on cultivar, maturity, and preparation. Not a standardized concentration for commercial powders.
2	Moringin (glucomoringin isothiocyanate); isothiocyanates	Isothiocyanate	Variable; not established	Not reliably quantified	NF-κB ↓; NRF2 ↑; anti-inflammatory and experimental anticancer effects	Generated from glucomoringin by myrosinase. Processing determines conversion. Link is to the general isothiocyanates product, not a moringin-specific entry.
3	Quercetin and derivatives	Flavonoids	0.207–7.57	1.04–37.85 mg	Anti-inflammatory; redox modulation; experimental antiproliferative activity	Contains free and conjugated forms depending on analytical method. Glycosides may be included in some measurements.
4	Kaempferol and derivatives	Flavonoids	ND–4.59	ND–22.95 mg	Cell-cycle modulation; apoptosis; anti-inflammatory activity	Includes glucosides, malonyl glucosides, and other conjugated forms. Some analyses report nondetectable concentrations.
5	Myricetin	Flavonoid	5.804	29.02 mg	Antioxidant; anti-inflammatory; experimental anticancer activity	Single reported measurement; not an established typical concentration.
6	Epicatechin	Flavanol	5.68	28.4 mg	Antioxidant and anti-inflammatory signaling	Reported in freeze-dried leaves. No separate database product identified.
7	Chlorogenic acid	Phenolic acid	0.018–0.489	0.09–2.45 mg	Antioxidant; metabolic and inflammatory regulation	Concentrations depend on extraction and analytical methods.
8	Caffeic acid	Phenolic acid	0.409–0.536	2.05–2.68 mg	Antioxidant and anti-inflammatory effects	Some studies report nondetectable concentrations.
9	Gallic acid	Phenolic acid	ND–1.034	ND–5.17 mg	Antioxidant; experimental antiproliferative effects	Highly variable analytical recovery.
10	Ferulic acid	Phenolic acid	0.078–0.128	0.39–0.64 mg	Antioxidant; cytoprotective effects	Reported in dried leaf preparations.
11	Lutein	Carotenoid	1.02	5.1 mg	Antioxidant; retinal and neuronal protection	Reported in freeze-dried leaves.
12	Beta-carotene	Carotenoid	0.163–0.66	0.82–3.3 mg	Provitamin A; antioxidant activity	Concentration varies with drying and storage.
13	Vitamin E (tocopherols)	Vitamin	0.7445–1.22	3.72–6.1 mg	Lipid-phase antioxidant activity	Different tocopherol forms and analytical methods may be represented.
14	Isorhamnetin	Methylated flavonoid	0.118–0.72	0.59–3.6 mg	Anti-inflammatory; experimental antiproliferative activity	No separate product identified. Methylated quercetin derivative.
15	Rutin (quercetin-3-O-rutinoside)	Flavonoid glycoside	0.390	1.95 mg	Antioxidant; anti-inflammatory; vascular protection	Direct published measurement in dried leaves. Rutin is a quercetin glycoside and must not be double-counted if total quercetin includes conjugates.
16	Ellagic acid	Polyphenolic acid	ND–0.189	ND–0.945 mg	Antioxidant; experimental anticancer activity	Low or nondetectable in some samples; limited systemic bioavailability of free ellagic acid.
17	o-Coumaric acid	Phenolic acid	6.457	32.285 mg	Antioxidant and anti-inflammatory activity	Single reported freeze-dried leaf measurement. Not interchangeable with p-coumaric acid.
18	p-Coumaric acid	Phenolic acid	ND	Not quantified	Antioxidant; anti-inflammatory effects	Not detected in the referenced freeze-dried leaf analysis. Separate isomer from o-coumaric acid.

Notes: ND = not detected; DW = dry weight. Values are literature measurements from different cultivars, drying procedures, extraction protocols, and analytical methods. They are not necessarily representative of retail leaf powder. The 5 g amounts are theoretical conversions, not measured oral exposure or bioavailability. Glycosides, aglycones, and precursor-derived products must not be double-counted.

Interpretation: ND means not detected. The amount per 5 g is a mathematical conversion of reported analytical values, not an expected dose from a commercial product. Glucomoringin and moringin must not be added together as independent constituents because moringin is formed from its precursor. Flavonoid measurements can include different free and conjugated forms.

Cancer-Related Mechanisms

Rank	Pathway / Axis	Cancer Cells	Normal Cells	TSF	Primary Effect	Notes / Interpretation
1	Mitochondrial apoptosis	Bax ↑; Bcl-2 ↓; ΔΨm ↓; cytochrome-c ↑; caspase-9 and caspase-3/7 ↑	↔ or apoptosis ↓ (context-dependent)	R, G	Apoptotic cell death	Among the most reproducible anticancer phenotypes across several leaf extracts and isolated fractions; evidence remains predominantly cellular and animal.
2	ROS and oxidative stress	ROS ↑ (context-dependent); oxidative stress ↑	ROS ↓; SOD ↑; catalase ↑; GPx ↑; GSH preservation ↑	P, R	Selective redox stress	Biphasic response is important. Pro-oxidant activity occurs in several cancer models, whereas antioxidant activity predominates in many non-cancer models.
3	NF-κB inflammatory and survival signaling	NF-κB ↓; p65 ↓; inflammatory survival signaling ↓	NF-κB ↓ (inflammatory models)	R, G	Survival and inflammatory signaling suppression	Repeatedly reported for leaf-derived preparations and relevant to both tumor survival and inflammatory signaling.
4	Cell-cycle regulation	p21 ↑; p53 ↑ (model-dependent); G1 or G2/M arrest ↑	↔	G	Cytostasis	Phase of arrest varies by tumor type and preparation. Some leukemia models show p21-dependent effects without significant p53 modulation.
5	PI3K and AKT survival signaling	AKT signaling ↓ or altered (model-dependent)	↔ or AKT ↑ during neuroprotection	R, G	Growth and survival suppression	Direction is strongly tissue-dependent; activation of AKT can be protective in stressed neurons, so this is not a universal inhibitory action of Moringa.
6	MEK ERK and stress MAPK signaling	MEK/ERK ↓ in some models; JNK/p38 modulation (model-dependent)	↔	R, G	Growth suppression and apoptotic signaling	Dalton lymphoma studies support MEK/ERK inactivation, while other preparations produce different MAPK signatures.
7	Invasion angiogenesis and metastatic signaling	Migration ↓; MMP-associated signaling ↓; VEGF-associated signaling ↓ (model-dependent)	↔	G	Anti-invasive and anti-angiogenic activity	Supported by selected experimental models but less consistent than apoptosis, redox, and NF-κB effects.
8	Chemosensitization	Cisplatin cytotoxicity ↑	Not established	G	Chemotherapy sensitization	Synergy has been demonstrated in pancreatic cancer cells with aqueous leaf extract; clinical validation is absent.
9	NRF2 ARE antioxidant response	NRF2 modulation (context-dependent)	NRF2 ↑; antioxidant and detoxification enzymes ↑	R, G	Cytoprotection and chemoprevention	More convincing as a normal-tissue protective or prevention mechanism than as a direct mechanism against established cancer; persistent NRF2 activation could theoretically protect some tumors.
10	Clinical Translation Constraint	Crude-extract activity commonly requires high concentrations	Oral leaf use generally produces dietary or nutraceutical exposure	G	Exposure and standardization limitation	Plant part, cultivar, drying, extraction, myrosinase activity, glucomoringin conversion, and constituent bioavailability vary substantially. Human anticancer exposure-response relationships have not been established.

P: 0–30 min R: 30 min–3 hr G: >3 hr

Alzheimer’s disease relevance: Moringa oleifera has meaningful but still preclinical AD relevance. Animal and cellular studies report reductions in amyloidogenic processing and Aβ burden, inhibition of Aβ aggregation, improvement of synaptic proteins and cognitive performance, antioxidant and anti-inflammatory activity, and acetylcholinesterase inhibition. Reported targets include BACE1 ↓, AEP ↓, Aβ ↓, IDE ↑, NEP ↑, LRP1 ↑, PSD95 ↑, synapsin-related signaling ↑, oxidative stress ↓, and AChE ↓. These findings justify an AD section in the database, but no adequate human trial currently establishes efficacy for prevention or treatment of Alzheimer’s disease.

Alzheimer’s Disease Mechanisms

Rank	Pathway / Axis	Modulation	TSF	Primary Effect	Notes / Interpretation
1	Amyloid production and clearance	BACE1 ↓; AEP ↓; Aβ ↓; IDE ↑; NEP ↑; LRP1 ↑	G	Reduced amyloid burden	Strong preclinical evidence in APP/PS1 and related experimental models.
2	Aβ aggregation	Aβ aggregation ↓	R, G	Reduced amyloid assembly	Recent biophysical and cellular work shows Moringa leaf polyphenol-rich aqueous extracts can interfere with Aβ1-42 aggregation.
3	Oxidative stress and antioxidant defenses	ROS ↓; SOD ↑; catalase ↑; GPx ↑	P, R, G	Neuroprotection	One of the most consistently reported neuroprotective actions.
4	Synaptic plasticity	PSD95 ↑; synapsin-related signaling ↑; BDNF ↑ (model-dependent)	G	Synaptic preservation	Associated with improved memory and learning phenotypes in preclinical models.
5	Cholinergic signaling	AChE ↓; BChE ↓ (compound-dependent); ACh availability ↑	R, G	Cholinergic support	Supported predominantly by enzyme, cellular, and animal studies rather than clinical AD trials.
6	Neuroinflammation	NF-κB ↓; inflammatory cytokines ↓	R, G	Anti-neuroinflammatory activity	Likely interacts with antioxidant and amyloid-related mechanisms.
7	Neuronal survival and mitochondrial function	AKT CREB signaling ↑; mitochondrial dysfunction ↓; apoptosis ↓	R, G	Neuronal survival	Direction contrasts with the AKT suppression sometimes sought in cancer and illustrates the strong tissue dependence of Moringa signaling.
8	Clinical Translation Constraint	Human AD efficacy not established	G	Translation limitation	Extract standardization, CNS exposure, active constituent PK, effective human dose, and long-term safety require clinical investigation.

P: 0–30 min R: 30 min–3 hr G: >3 hr

Home